Zoetis Inc. (ZTS)

Market Cap	74.37B
Revenue (ttm)	9.15B
Net Income (ttm)	2.43B
Shares Out	451.17M
EPS (ttm)	5.32
PE Ratio	31.00
Forward PE	26.78
Dividend	$1.73 (1.05%)
Ex-Dividend Date	Oct 31, 2024

Volume	6,129,526
Open	163.76
Previous Close	163.52
Day's Range	163.53 - 166.39
52-Week Range	144.80 - 200.53
Beta	0.88
Analysts	Strong Buy
Price Target	220.33 (+33.66%)
Earnings Date	Feb 11, 2025

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 14,100
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.

Analyst Forecast

According to 9 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $220.33, which is an increase of 33.66% from the latest price.

Price Target

$220.33

(33.66% upside)

Analyst Consensus: Strong Buy